Trial Protocol ID USOR 22187_D926XC00001_TROPION

Trial Description

A Phase 3 Open-Label, Randomised Study of Datopotamab Deruxtecan (Dato-Dxd) with or without Durvalumab versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple-Negative Breast Cancer who have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)

Contact us regarding Clinical Trials at or call us at 877-664-7724


  • Yousuf A. Gaffar, M.D.

Disease Types


  • AstraZeneca NCT ID

  • NCT05629585